Loading…

Loading grant details…

Active H2020 European Commission

Building a reproducible single-cell experimental workflow to capture tumour cell persistence

€15.32M EUR

Funder European Commission
Recipient Organization Stichting Oncode Institute
Country Netherlands
Start Date Jul 01, 2021
End Date Jun 30, 2026
Duration 1,825 days
Number of Grantees 17
Roles Participant; Third Party; Coordinator
Data Source European Commission
Grant ID 101007937
Grant Description

It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by developing best practices, standard operating procedures (SOPs), and high-quality FAIR data, with the ultimate aim to empower them to unravel therapeutic resistance.

Such, that the community can identify urgently needed markers to predict, prevent, and target tumour resistance.

Cancer takes 9.6 million lives each year, 90% of which result from untreatable metastatic relapse occurring after initially (seemingly) effective treatment.

Therapeutic resistance is hence a primary cause of cancer death that clinically cannot be predicted, prevented, or treated.

Addressing the urgent need for smarter therapeutic strategies is however held back by the lack of standardised experimental approaches that enable studying the biology of residual disease and drug tolerant persister cells in full detail.

This need encompasses best practices for single-cell sequencing, advanced modelling techniques using patient-derived organoids and xenografts, and data FAIRification for integrated experiments.

To address this need, PERSIST-SEQ brings together globally leading groups in single-cell sequencing technologies, cancer modelling and therapeutic resistance.

Furthermore, the consortium has a broad range of clinical samples, cell lines, 3D models (PDX and PDOs) and mice models (GEMMs) at its disposal that can be leveraged to answer a broad range of emerging questions.

This positions the consortium excellently to (1) design and standardise single-cell experimental approach to study the biology of therapeutic resistance and (2) initiate the largest single-cell profiling initiative on therapeutic resistance.

Importantly, PERSIST-SEQ is organised such that it can quickly adapt to emerging insights and techniques during the project, and that ensures the capture of learnings in manners that stimulate replication of workflows elsewhere.

All Grantees

Single Cell Discoveries Bv; Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio); Stichting Lygature; Stichting Hubrecht Organoid Technology; Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw; Genome Research Limited; Astrazeneca Ab; Stichting Oncode Institute; Transgene Sa; Merck Kommanditgesellschaft Auf Aktien; Charles River Discovery Research Services Germany Gmbh; Fundacio Institut de Recerca Biomedica (Irb Barcelona); Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis; Xenopat Sl; Bayer Aktiengesellschaft; Fondazione Del Piemonte Per L'Oncologia; Ifom-Istituto Fondazione Di Oncologia Molecolare Ets

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant